Stay updated on Phase II Anti-PD1 Epigenetic Therapy Clinical Trial
Sign up to get notified when there's something new on the Phase II Anti-PD1 Epigenetic Therapy Clinical Trial page.

Latest updates to the Phase II Anti-PD1 Epigenetic Therapy Clinical Trial page
- Check7 days agoChange DetectedThe page has been updated to version v2.16.5, and the previous version v2.16.4 has been removed. Notably, the information regarding the modernization of ClinicalTrials.gov data ingest scheduled for July 2025 has been deleted.SummaryDifference0.9%
- Check14 days agoNo Change Detected
- Check21 days agoChange DetectedThe expected modernization date for the ClinicalTrials.gov data ingest has been updated from June 2025 to July 2025.SummaryDifference0.7%
- Check28 days agoNo Change Detected
- Check36 days agoChange DetectedThe web page has been updated from version 2.16.1 to version 2.16.2.SummaryDifference0.1%
- Check43 days agoChange DetectedThe web page has been updated to announce the modernization of the ClinicalTrials.gov data ingest scheduled for June 2025, allowing API users to provide input before implementation. Additionally, the revision number has been updated from v2.15.2 to v2.16.1.SummaryDifference1%
- Check71 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.SummaryDifference0.1%
- Check86 days agoChange DetectedThe webpage has undergone significant updates, including the removal of detailed study criteria and objectives related to a Phase II study of epigenetic therapy for metastatic non-small cell lung cancer, while adding new collaborators and identifiers related to ongoing research.SummaryDifference44%
Stay in the know with updates to Phase II Anti-PD1 Epigenetic Therapy Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Phase II Anti-PD1 Epigenetic Therapy Clinical Trial page.